Abbvie Sculpts Position In Aesthetics Space With Allergan Acquisition
Abbvie is taking on Allergan's aesthetics portfolio as part of its $63bn takeover deal. The acquisition includes Allergan's CoolSculpt body contouring system and a new FDA-approved device for muscle strengthening.
You may also be interested in...
AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.
Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.